Overview

Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This double-blind, placebo-controlled, single ascending dose study is designed to demonstrate safety, tolerability and pharmacokinetics of SKI-O-703 in healthy volunteers. The results of this study will guide selection of dose levels for future multiple dose studies in healthy volunteers and adult patients with moderately to severely active rheumatoid arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Oscotec Inc.
Collaborator:
PPD